These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23228667)

  • 1. Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide.
    Reznik Y; Bertherat J; Borson-Chazot F; Brue T; Chanson P; Cortet-Rudelli C; Delemer B; Tabarin A; Bisot-Locard S; Vergès B
    Diabetes Metab; 2013 Feb; 39(1):34-41. PubMed ID: 23228667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations.
    Colao A; De Block C; Gaztambide MS; Kumar S; Seufert J; Casanueva FF
    Pituitary; 2014 Apr; 17(2):180-6. PubMed ID: 23564338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 12-month phase 3 study of pasireotide in Cushing's disease.
    Colao A; Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Schoenherr U; Mills D; Salgado LR; Biller BM;
    N Engl J Med; 2012 Mar; 366(10):914-24. PubMed ID: 22397653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pasireotide: a review of its use in Cushing's disease.
    McKeage K
    Drugs; 2013 May; 73(6):563-74. PubMed ID: 23605695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of anti-somatostatin agents on glucose metabolism.
    Vergès B
    Diabetes Metab; 2017 Oct; 43(5):411-415. PubMed ID: 28579289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly.
    Silverstein JM
    Pituitary; 2016 Oct; 19(5):536-43. PubMed ID: 27405306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment:
    Feldt-Rasmussen U; Bolanowski M; Zhang SL; Yu Y; Witek P; Kalra P; Kietsiriroje N; Piacentini A; Pedroncelli AM; Samson SL
    Front Endocrinol (Lausanne); 2024; 15():1250822. PubMed ID: 38577574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations.
    Trementino L; Cardinaletti M; Concettoni C; Marcelli G; Boscaro M; Arnaldi G
    Pituitary; 2015 Jun; 18(3):359-65. PubMed ID: 24952218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
    Boscaro M; Ludlam WH; Atkinson B; Glusman JE; Petersenn S; Reincke M; Snyder P; Tabarin A; Biller BM; Findling J; Melmed S; Darby CH; Hu K; Wang Y; Freda PU; Grossman AB; Frohman LA; Bertherat J
    J Clin Endocrinol Metab; 2009 Jan; 94(1):115-22. PubMed ID: 18957506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center.
    Simeoli C; Ferrigno R; De Martino MC; Iacuaniello D; Papa F; Angellotti D; Pivonello C; Patalano R; Negri M; Colao A; Pivonello R
    J Endocrinol Invest; 2020 Jan; 43(1):57-73. PubMed ID: 31313243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on "real-world evidence".
    Pivonello R; Arnaldi G; Scaroni C; Giordano C; Cannavò S; Iacuaniello D; Trementino L; Zilio M; Guarnotta V; Albani A; Cozzolino A; Michetti G; Boscaro M; Colao A
    Endocrine; 2019 Jun; 64(3):657-672. PubMed ID: 30968338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
    Schopohl J; Gu F; Rubens R; Van Gaal L; Bertherat J; Ligueros-Saylan M; Trovato A; Hughes G; Salgado LR; Boscaro M; Pivonello R;
    Pituitary; 2015 Oct; 18(5):604-12. PubMed ID: 25537481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review.
    Shimon I; Rot L; Inbar E
    Pituitary; 2012 Dec; 15(4):608-13. PubMed ID: 22918543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
    Fleseriu M; Petersenn S; Biller BMK; Kadioglu P; De Block C; T'Sjoen G; Vantyghem MC; Tauchmanova L; Wojna J; Roughton M; Lacroix A; Newell-Price J
    Clin Endocrinol (Oxf); 2019 Dec; 91(6):776-785. PubMed ID: 31465533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
    Pedroncelli AM
    Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome.
    Trementino L; Michetti G; Angeletti A; Marcelli G; Concettoni C; Cardinaletti C; Polenta B; Boscaro M; Arnaldi G
    Horm Metab Res; 2016 May; 48(5):290-8. PubMed ID: 27127913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pasireotide.
    Prescrire Int; 2013 Nov; 22(143):257-9. PubMed ID: 24427831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Treatment of Cushing's Disease.
    Pivonello R; De Leo M; Cozzolino A; Colao A
    Endocr Rev; 2015 Aug; 36(4):385-486. PubMed ID: 26067718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cushing's disease: current medical therapies and molecular insights guiding future therapies.
    Lau D; Rutledge C; Aghi MK
    Neurosurg Focus; 2015 Feb; 38(2):E11. PubMed ID: 25639313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.
    Petersenn S; Salgado LR; Schopohl J; Portocarrero-Ortiz L; Arnaldi G; Lacroix A; Scaroni C; Ravichandran S; Kandra A; Biller BMK
    Endocrine; 2017 Jul; 57(1):156-165. PubMed ID: 28597198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.